The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
PV-ARC: ELN Clinical Signs and Symptoms for thrombotic risk in patients with PV treated with HU
|
The observational, longitudinal, retrospective, and prospective PV-ARC study (NCT06134102) aimed to investigate the impact of clinical and laboratory characteristics of PV on patients prognoses.1 A sub-analysis from the study presented during the 66th ASH Annual Meeting and Exposition by Palandri assessed the incidence of thrombosis among 739 patients with PV treated with first-line hydroxyurea (HU), and the impact of the ELN 2021 criteria for initiating cytoreductive therapy.1 |
| Key learnings |
| The IRR of thrombosis was higher in HR-THRO patients (3.0) vs LR-patients (1.1; p = 0.006) and HR-AGE patients (1.3; p = 0.002); within the HR-THRO group, IRR was highest in patients with both older age and previous thrombosis (3.5) vs thrombosis only (1.9). |
| Patients with no ELN CSSs had improved 5-year TFS vs patients with ELN CSSs across risk groups (LR, 100% vs 86.4; HR-AGE, 97.8% vs 91.4%; HR-THRO, 88.1% vs 79.5%). |
| Progressive splenomegaly (HR, 6.10; 95% CI, 1.70–21.88; p = 0.005), inadequate hematocrit control (HR, 2.20; 95% CI, 1.36–3.54; p = 0.001), and relevant CVRFs (HR, 2.56; 95% CI, 1.09–6.00; p = 0.03) were significant predictors of thrombotic risk and may be used to inform more aggressive and personalized management strategies. |
| Results suggested that ELN CSSs can identify patients with PV at increased thrombotic risk across all conventional risk categories. |
Abbreviations: ASH, American Society of Hematology; CI, confidence interval; CSSs, Clinical Signs and Symptoms; CVRF, cardiovascular risk factor; ELN, European LeukemiaNet; HR, hazard ratio; HR-AGE, high-risk, age >60 years; HR-THRO, high-risk, previous thrombosis; IRR, incidence ratio rate; LR, low-risk; PV, polycythemia vera.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
